Company profilePharmaceutical#850 of 1,318 in Pakistan✓ No DRAP alerts

Bajwa Pharmaceuticals (Pvt.) Ltd. DML: 000805

Pharmaceutical company · 8 brands · 20 molecules

Ranked #143 of 146 companies in Antiemetics & Antinauseants

8 registered products 13 pharmaceutical brands 20 distinct molecules 0 DRAP alerts

Company overview

8
registered products
13
pharmaceutical brands
20
distinct molecules
6
therapeutic classes
0
DRAP alerts

Bajwa Pharmaceuticals (Pvt.) Ltd. DML: 000805 is a pharmaceutical manufacturer registered with the Drug Regulatory Authority of Pakistan, holding 8 product registrations across 20 distinct molecules. Its portfolio is concentrated in Antiemetics & Antinauseants and Muscle Relaxant. It has no DRAP recall, shortage or safety notices on record.

Compiled from the DRAP registry, DRAP approved prices and DRAP alerts, with observed retail from DVAGO and Servaid. Data as of 2026-07-30.

Top molecules by brand count

Bupivacaine2 brands
Ondansetron ...... 8 Mg1 brand
Ondansetron Hci ...... 8 Mg1 brand
Propofol1 brand
Atracurium ...... 30 Mg1 brand
Atracurium1 brand
Atracurium ...... 10 Mg1 brand
Atracurim ...... 50 Mg1 brand
Frusemide ...... 20 Mg1 brand

Therapeutic classes

Antiemetics & Antinauseants · 1Muscle Relaxant · 1Pain Management · 1Cardiac Care · 1Diuretic · 1Vitamin A, D & Combinations · 1

Conditions treated

Muscle Relaxant/Spasm · 1Urine Retention · 1

Price band (DRAP official ceilings)

Registered products priced by source
DRAP-official11 products · Rs 167.5 – Rs 5,156.19
Servaid2 products · Rs 282 – Rs 806
Median across source: Rs 778.24

Regulatory record

No DRAP alerts on record

No recalls, shortage notices or safety alerts involving this company’s products appear in the DRAP alert feed we track. Median across all 1,318 mapped companies is zero — 1,165 of them also have a clean sheet.

Competitive set

Companies whose registered portfolio overlaps most with this one.

Get the full profile for Bajwa

This page is a summary. The full company brief adds every registration with its approved ceiling and approval date, per-molecule competitive position, price positioning against the category, and a launch shortlist built from the whitespace above.

Request this brief See what’s included

Company data as of 2026-07-30. Brand and molecule counts from the DRAP registry and observed retail sources.

For medicine intelligence and professional reference only. Not medical advice.